Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
NCT05163080Phase 2Active, not recruiting
- Sponsor
- MimiVax
- Start
- Nov 2021
- Primary completion
- Aug 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SurVaxM in glioblastoma (GBM), sponsored by MimiVax. Started Nov 2021; status: active, not recruiting.
02
Drugs
SurVaxM
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05163080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163080.